CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 10,010 enrolled
Drug / intervention
Active Clonidine +3 moredrug
Likely dose
Active Clonidine 0.1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01082874
NCT01082874Phase 3Completed

A Large, International, Placebo-controlled, Factorial Trial to Assess the Impact of Clonidine and Acetyl-salicylic Acid (ASA) in Patients Undergoing Noncardiac Surgery Who Are at Risk of a Perioperative Cardiovascular Event

Hamilton Health Sciences Corporation·interventional·Posted Mar 9, 2010·Updated Aug 25, 2016

In Brief

A Phase 3 clinical trial evaluating Active Clonidine, Placebo Clonidine, and 2 other interventions for Cardiovascular Disease. Completed, enrolled 10,010 participants across 23 sites in 23 countries.

Detailed Summary

Major surgeries not involving the heart are common, and major heart problems during or after such surgeries represent a large population health problem. Few treatments to prevent heart problems around the time of surgery have been tested. There is encouraging data suggesting that small doses of Acetyl-Salicylic Acid (ASA) and Clonidine, which are two medications, given individually for a short period before and after major surgeries may prevent major heart problems. The POISE-2 Trial is a large international study to test if ASA and Clonidine can prevent heart attacks and deaths from heart problems around the time of surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Denmark, France, Germany, Hong Kong, India, Italy, Malaysia, New Zealand, Pakistan, Peru, South Africa, Spain, Switzerland, United Kingdom, United States
CollaboratorsMcMaster University

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 9, 2010
Enrollment StartJul 1, 2010
Primary CompletionMar 1, 2014
Study CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 16.3 years ago

Interventions

Active Clonidinedrug

Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.

Placebo Clonidinedrug

Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.

Active ASAdrug

Pre-op (goal 2-4 hours): 2 x 100mg oral tablets. Post-op: patients ingest one tablet a day (100 mg ASA) for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery

Placebo ASAdrug

Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery